Integrum's OPRA™ Implant System gets FDA approval for clinical study on below-knee amputations

Published

MÖLNDAL, Sweden, Oct. 30, 2023 /PRNewswire/ -- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company's OPRA™ Implant system is approved by FDA to be used in a clinical study on below-knee amputations in the US.

The clinical study will be important for the future approval of the OPRA™ Implant System on the below-knee amputation level, which is the most frequent amputation level. The study will be performed by the Walter Reed National Military Medical Center.

"This is an important milestone in the expansion of indications for our OPRA™ Implant System," said Rickard Brånemark, CEO of Integrum.

For more information please contact:Rickard Brånemark, CEOPhone: +46 (0) 70 846 10 61E-mail: rickard.branemark@integrum.se

Jörgen Svanström, CFOPhone: + 46 (0) 70 734 96 60E-mail: Jorgen.svanstrom@integrum.se

Certified Adviser

Erik Penser Bank is Certified Adviser.

The following files are available for download:

https://mb.cision.com/Public/17531/3865375/ae332572d5827e27.pdf

2023-10-30 Integrum PR IDE TTA

 

Cision View original content:https://www.prnewswire.com/news-releases/integrums-opra-implant-system-gets-fda-approval-for-clinical-study-on-below-knee-amputations-301971151.html

SOURCE Integrum AB

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.